N-homocysteinylated Huntingtin in Huntington's Disease

Status: Not yet recruiting
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin) human control cell lines, unmutated Huntingtin

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Patient with the symptomatic or presymptomatic Huntington's disease gene (CAG >= 36)

• Molecularly confirmed Huntington's disease

• Patient 18 years of age and older

• Person affiliated to or benefiting from a social security assurance

Contact Information
Primary
Mathilde Renaud, MD, PhD
m.renaud2@chru-nancy.fr
03 83 15 36 22
Backup
Nathalie Keil
n.keil@chru-nancy.fr
03 83 15 52 79
Time Frame
Start Date: April 1, 2022
Estimated Completion Date: May 1, 2023
Participants
Target number of participants: 32
Treatments
Experimental: presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
Experimental: symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
Experimental: human control cell lines, Unmutated Huntingtin
human control cell lines, Unmutated Huntingtin
Sponsors
Leads: Central Hospital, Nancy, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials